Biotech

All Articles

Ascendis' dwarfism medicine favorites in phase 3, threatens BioMarin

.Ascendis Pharma has actually become a possible hazard to BioMarin's Voxzogo, stating stage 3 develo...

Despite ph. 3 miss, Alkeus sees course in advance for eye health condition resource

.Though Alkeus Pharmaceuticals' dental eye health condition property fell short to substantially dec...

Kairos goes public along with $6M IPO to fund tests of cancer medication

.With a trio of biotechs reaching the Nasdaq on Friday, it was actually simple to miss out on a smal...

Vaccine as well as Keytruda combination reliable in squamous cell carcinoma

.Immune system gate preventions are the superheroes of cancer cells treatment. Drugs like Bristol My...

Cue Biopharma mark time J&ampJ vet as CBO-- Chutes &amp Ladders

.Welcome to recently's Chutes &amp Ladders, our roundup of considerable leadership hirings, firings ...

Regeneron's Opdualag competitor shows 57% feedback rate

.Regeneron is back along with long-lasting consequence for its own LAG-3 inhibitor and also PD-1 pre...

AstraZeneca posts data on in-house rivals to AbbVie, Pfizer ADCs

.AstraZeneca has actually discussed a very early consider the efficiency of its in-house antibody-dr...

iTeos- GSK's TIGIT celebrity shows purposeful improvement

.After introducing a stage 3 launch based upon positive midstage results, iTeos and also GSK are act...

More joint FDA may increase unusual disease R&ampD: report

.The FDA must be much more available and also collective to let loose a surge in approvals of unusua...

Zenas, MBX, Bicara head to Nasdaq in scorching time for biotech IPOs

.It is actually an extraordinarily occupied Friday for biotech IPOs, with Zenas BioPharma, MBX and B...